Blog
RSS FeedPosted by Michael Wonder on 06 Jul 2022
Setmelanotide for the treatment of patients with obesity caused by LEPR or POMC deficiency
6 July 2022 - NICE has issued fvidence-based recommendations on setmelanotide (Imcivree) for treating obesity caused by LEPR or POMC ...
Posted by Michael Wonder on 05 Jul 2022
NICE recommends three more treatments for atopic dermatitis
30 June 2022 - Doctors now have three more prescribing options for patients with severe atopic dermatitis who do not ...
Posted by Michael Wonder on 30 Jun 2022
Zanubrutinib for the treatment of adults with Waldenström’s macroglobulinaemia
29 June 2022 - NICE has published a second appraisal consultation document on the use of zanubrutinib for the treatment ...
Posted by Michael Wonder on 29 Jun 2022
NICE publishes its 800th technology assessment
29 June 2022 - TAs 799 and 800 are for the same technology. ...
Posted by Michael Wonder on 23 Jun 2022
NICE opts to reject Acorda’s MS drug Fampyra
22 June 2022 - NICE has announced its decision to reject Fampyra – also known as fampridine – for use ...
Posted by Michael Wonder on 16 Jun 2022
New treatment to increase the chances of a successful kidney transplant recommended by NICE
16 June 2022 - A new treatment that increases the chance of a successful kidney transplant has been recommended by ...
Posted by Michael Wonder on 15 Jun 2022
Another week, another terminated NICE appraisal
15 June 2022 - It should not come as a surprise that it is for a cancer medicine. ...
Posted by Michael Wonder on 10 Jun 2022
Hundreds of thousands set to benefit as NICE final draft guidance recommends new treatment to prevent heart attacks and strokes in people with raised blood fats
10 June 2022 - NICE has today published final draft guidance which recommends icosapent ethyl for reducing the risk of cardiovascular ...
Posted by Michael Wonder on 09 Jun 2022
Roxadustat for treating anaemia in people with chronic kidney disease
9 June 2022 - After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Document on the ...
Posted by Michael Wonder on 08 Jun 2022
Another new month, another terminated NICE appraisal
8 June 2022 - This time it is not for a cancer medicine. ...
Posted by Michael Wonder on 01 Jun 2022
NICE recommends UCB’s Fintepla for Dravet syndrome
1 June 2022 - UCB has announced that it has received a final appraisal determination from NICE recommending Fintepla (fenfluramine). ...
Posted by Michael Wonder on 01 Jun 2022
NICE recommends potentially life-changing treatment for people with short bowel syndrome
1 June 2022 - A potentially life-changing treatment has been recommended for people with short bowel syndrome who are aged ...
Posted by Michael Wonder on 01 Jun 2022
Filgotinib maleate for patients with moderate to severe active ulcerative colitis
1 June 2022 - NICE has published evidence based recommendations on the use of filgotinib maleate (Jyseleca) for the treatment ...
Posted by Michael Wonder on 26 May 2022
Romosozumab for treating severe osteoporosis
25 May 2022 - NICE has published evidence-based recommendations on the use of romosozumab for patients with severe osteoporosis. ...
Posted by Michael Wonder on 25 May 2022
New injectable immunotherapy treatment for rare form of triple negative breast cancer recommended by NICE
25 May 2022 - An estimated 100 people per year with triple negative breast cancer that has spread to other ...